Neuralstem, Inc. is focused on developing and commercializing of treatments for central nervous system disease based on transplanting human neural stem cells and small molecule drugs. The Company has developed and maintain a portfolio of patents and patent applications that form the base of its research and development efforts in the areas of neural stem cell research, small molecule research, and related technologies.
04/10/11Neuralstem shares jump over 13% on new stem cell patent
16/12/10Neuralstem Receives FDA Approval to Start Phase Ia Trial for Depression Drug
14/09/10Study Shows Neuralstem’s Stem Cells May Have Application To Treating Stroke
Recent Sector News
U.S. stocks were lower on Monday, weighed down by disappointing data from both China and Japan and continued Ukraine worries, with the S&P 500 retreating from its record high.
Pivotal Therapeutics (OTCQX:PVTTF) (CSE:PVO), a specialty pharmaceutical company focused on Omega-3 therapies for cardiovascular disease, has appointed James Connolly to its board of directors.
U.S. stocks rose on Thursday as jobless claims fell to a three month low and as investors considered attention-grabbing comments from Fed speakers.
Pivotal Therapeutics (OTCQX:PVTTF) (CSE:PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies, said it has raised $7.7 million through a debt financing, surpassing its previous capital raising goal.
Deal will see US giant collaborate with Xenetic on improved treatment for haemophilia to be administered much less frequently.
Advanced Proteome Therapeutics to progress two anti-cancer agents to further animal testing after encouraging results
Advanced Proteome Therapeutics (CVE:APC) has discovered that two molecules from the first series of potential anti-cancer agents it is testing have shown "statistically significant retardation" of tumour growth in mice.
Investors interested in Neuralstem recently viewed
- Nanobiotix (EURONEXT: NANO) .
- OncoSil Medical Limited (ASX: OSL) New technology to provide safe radiation treatments
- Acuvax soon to be renamed Biolife Science Limited (asx: ACU) .
- Silence Therapeutics (AIM: SLN) A leader in RNAi therapeutics
- Medical Australia Limited (ASX: MLA) Medical devices developed, manufactured and distributed in Australia.